Inspharma

InSPharma is a Spanish biotechnology company specializing in the discovery and development of new drugs targeting G protein-coupled receptors (GPCRs). A spin-off from the University of Santiago de Compostela, the company utilizes its proprietary screening platforms to identify small molecule modulators for metabolic and central nervous system disorders. Their lead programs focus on melanin-concentrating hormone receptor 1 (MCHR1) for the treatment of obesity and non-alcoholic steatohepatitis (NASH). In addition to internal drug discovery, InSPharma provides specialized pharmacological screening and profiling services to the global pharmaceutical industry. The company leverages deep expertise in molecular pharmacology to accelerate the transition from hit identification to lead optimization.